Steve Scala
Stock Analyst at TD Cowen
(2.76)
# 1,921
Out of 4,735 analysts
31
Total ratings
69.23%
Success rate
12.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Scala
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Buy | $195 → $225 | $172.61 | +30.35% | 12 | Oct 7, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $59 | $57.04 | +3.44% | 3 | Oct 7, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $90 → $95 | $67.96 | +39.79% | 1 | Aug 12, 2024 | |
| MRK Merck & Co. | Upgrades: Outperform | $125 → $135 | $96.24 | +40.27% | 1 | Jan 4, 2024 | |
| PFE Pfizer | Downgrades: Market Perform | $32 | $26.64 | +20.12% | 1 | Jan 4, 2024 | |
| LLY Eli Lilly | Maintains: Outperform | $430 → $500 | $742.35 | -32.65% | 8 | May 23, 2023 | |
| NVS Novartis AG | Downgrades: Market Perform | $110 → $105 | $99.73 | +5.28% | 4 | Feb 1, 2021 | |
| RPRX Royalty Pharma | Initiates: Outperform | $55 | $30.30 | +81.52% | 1 | Jul 13, 2020 |
AbbVie
Oct 7, 2024
Maintains: Buy
Price Target: $195 → $225
Current: $172.61
Upside: +30.35%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Hold
Price Target: $53 → $59
Current: $57.04
Upside: +3.44%
AstraZeneca
Aug 12, 2024
Maintains: Buy
Price Target: $90 → $95
Current: $67.96
Upside: +39.79%
Merck & Co.
Jan 4, 2024
Upgrades: Outperform
Price Target: $125 → $135
Current: $96.24
Upside: +40.27%
Pfizer
Jan 4, 2024
Downgrades: Market Perform
Price Target: $32
Current: $26.64
Upside: +20.12%
Eli Lilly
May 23, 2023
Maintains: Outperform
Price Target: $430 → $500
Current: $742.35
Upside: -32.65%
Novartis AG
Feb 1, 2021
Downgrades: Market Perform
Price Target: $110 → $105
Current: $99.73
Upside: +5.28%
Royalty Pharma
Jul 13, 2020
Initiates: Outperform
Price Target: $55
Current: $30.30
Upside: +81.52%